Post by GSK

We believe early intervention with disease modifying therapy is vital to prevent irreversible progression and organ damage in patients with lupus. At this year’s European Lupus Meeting we are sharing the latest data that highlights our long-term focus on improving the outcomes for those patients, through early intervention with advanced therapies. #SLEuro

Video Content